Alvotech Targets $6.4B Entyvio Market After Positive Biosimilar Study

REYKJAVIK, ICELAND – February 05, 2026 – Icelandic biotechnology firm Alvotech has announced a significant breakthrough in its quest to bring a more affordable alternative for a widely used inflammatory bowel disease (IBD) treatment to market. The company revealed positive top-line results from a pivotal clinical study for its biosimilar candidate to Entyvio (vedolizumab), a blockbuster drug that generated approximately $6.4 billion in global sales in 2025.

The announcement signals a major step forward in the development of both subcutaneous (AVT80) and intravenous (AVT16) versions of the biosimilar. This success positions Alvotech to pursue regulatory approval, potentially introducing fierce competition into the lucrative market for treating chronic conditions like Ulcerative Colitis and Crohn's disease and offering new hope for patients facing high treatment costs.

A Pivotal Scientific Milestone

Alvotech confirmed that its pharmacokinetic (PK) study, designated AVT80-GL-P01, successfully met all of its primary endpoints. The randomized, double-blind study was designed to prove that Alvotech’s biosimilar behaves in the human body in the same way as the originator drug, Entyvio. It rigorously compared the pharmacokinetics, safety, and immunogenicity of AVT80 against Entyvio in healthy adult participants receiving a single subcutaneous injection.

Meeting these endpoints is a critical hurdle in the biosimilar development process, providing the foundational data required by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). According to the company, this single pivotal study is sufficient to support applications for both its subcutaneous and intravenous formulations, streamlining its path to market.

“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” said Joseph McClellan, Alvotech's Chief Operating Officer, in the company's official press release. He added that the achievement “underlines the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities.”

Disrupting a Multi-Billion Dollar Market

The financial stakes are immense. Entyvio, manufactured by Takeda, has become a cornerstone therapy for moderate to severe Ulcerative Colitis and Crohn’s disease due to its gut-selective mechanism, which minimizes systemic side effects common with other biologics. Its market dominance has translated into staggering revenues, with Takeda's own reports showing sales surpassed $6 billion in fiscal year 2024.

The broader market for IBD treatments is projected to expand significantly, with estimates suggesting it could grow from over $25 billion in 2025 to more than $36 billion by 2032. With key patents for Entyvio expected to expire after 2026, the timing of Alvotech's successful study could not be more opportune. The potential market entry of a vedolizumab biosimilar is poised to capture a substantial portion of this revenue by offering a clinically equivalent but more cost-effective alternative.

Furthermore, external pressures are already mounting on high-cost biologics. In the United States, Entyvio has been identified as a candidate for Medicare price negotiations under the Inflation Reduction Act, with potential price cuts taking effect in 2028. This regulatory pressure could make healthcare systems and payers even more receptive to adopting lower-priced biosimilars to manage budgets.

The Promise of Greater Access and Affordability

For the millions of people worldwide living with IBD, the potential arrival of a vedolizumab biosimilar is about more than market dynamics; it represents a tangible hope for improved access and reduced financial burden. Chronic conditions like Crohn's disease and Ulcerative Colitis require lifelong management, and the high cost of biologic therapies can be a significant barrier to care.

Biosimilars have a proven track record of driving down healthcare costs. The introduction of competition typically forces price reductions on both the originator drug and the new biosimilar, leading to system-wide savings. This trend has been observed with biosimilars for other major IBD drugs, including Humira (adalimumab) and Stelara (ustekinumab)—products for which Alvotech has already successfully developed and marketed biosimilars through its global partnerships.

The development of both intravenous and subcutaneous versions of the Entyvio biosimilar is also strategic. While the intravenous version is administered in a clinical setting, the subcutaneous option offers patients the convenience of self-injection at home, a factor that has contributed significantly to Entyvio's own market growth. By offering both, Alvotech aims to provide a seamless alternative for patients and physicians, regardless of their preferred administration method.

Navigating a Complex Path to Patients

While the positive study results are a cause for optimism, the road to market launch remains complex. Alvotech must now compile its extensive data into comprehensive dossiers for submission to regulatory bodies. This review process is exhaustive, as regulators must be fully convinced of the product's similarity, safety, and efficacy before granting approval.

Upon approval, Alvotech will enter a competitive field. The IBD treatment landscape is crowded and dynamic, with established biologics, emerging novel therapies targeting different inflammatory pathways, and a growing number of other biosimilars. Physician and patient trust is paramount for adoption. Gaining that trust requires robust clinical data, extensive education, and a strong real-world performance record.

Here, Alvotech's experience and strategy provide a distinct advantage. The company focuses solely on biosimilars and has built a powerful global network of commercial partners, including Teva Pharmaceuticals in the U.S. and STADA in Europe, to handle marketing and distribution. This integrated model, combined with a pipeline of nine disclosed biosimilar candidates, positions Alvotech not just as a developer but as a formidable force in the global effort to make critical medicines more accessible.